Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Autor: Christian Pfister, Valentin Harter, Yves Allory, François Radvanyi, Stéphane Culine, G. Grawis, G. Pignot, A. Flechon, J.P. Fendler, C. Chevreau, M. Soulie, H. Mahammedi, L. Guy, B. Laguerre, G. Verhoest, A. Guillot, N. Mottet, F. Joly, A. Doerfler, S. Abadie-Lacourtoisie, A.R. Azzouzi, P. Mongiat, L. Geoffrois, P. Eschwege, F. Di Fiore, G. Roubaud, J.L. Hoepffner, P. Barthelemy, H. Lang, E. Voog, E. Mandron, J.M. Tourani, C. Serrrate, A. Colau, C. Saldana, A. de La Taille, T. Nguyen, F. Kleinclauss, Y. Loriot, J. Irani, J.C. Eymard, S. Larre, O. Huillard, M. Zerbib, F. Rolland, J. Rigaud, N. Houede, S. Droupy, G. Malouf, M. Roupret, M. El Demery, C. Legon, S. Vieillot, N. Letang, T. Lharidon, N. Gaschignard, W. Hilgers, J.L. Davin

Publikováno v: Contemporary Clinical Trials Communications, Vol 17, Iss , Pp - (2020)

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery.A total of

Externí odkaz: https://doaj.org/article/f43ed578297242ffbca2d23538b428ab

L’intensification du traitement du cancer de la prostate métastatique hormonosensible (MHSPC) est devenue un standard de prise en charge en France (étude profile)

Autor: C. Helissey, D. Maillet, B. Narciso, J. Berdah, I. Ouzaid, W. Hilgers, G. Fiard, T. Dubergé, N. Jovenin, D. Topart, J. Beauval, N. Didier, G. Roubaud

Publikováno v: Progrès en Urologie - FMC. 32:S3-S4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d690df65c35f16ad493875c227de8935
https://doi.org/10.1016/j.fpurol.2022.07.008

1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)

Autor: P. Barthelemy, C. Thibault, E. Voog, J-C. Eymard, A. Ravaud, A. Flechon, C. Abraham Jaillon, W. Hilgers, S. Le Moulec, M. Chasseray, D. Pouessel, Y.E. Amela, V. Lorgis, E. Nicolas, E. Kazan, G. Denechere, M-N. Solbes, P. Lambert, Y. Loriot

Publikováno v: Annals of Oncology. 33:S1341-S1342

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcb0f65bd5698d33a6b1ddd4303b28a2
https://doi.org/10.1016/j.annonc.2022.07.1835

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Autor: O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I. Monnet, G. Jeannin, J. Mazières, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V. Westeel, P. Brun, A. Langlais, F. Morin, P.J. Souquet, N. Girard

Publikováno v: ESMO Open
ESMO Open, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩
ESMO Open, European Society for Medical Oncology, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩

Background Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). Materials a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca79719ac7e0d0d9f96b94dc3cb9c4f
https://hal.sorbonne-universite.fr/hal-03512207/document

Étude de vraie vie d’utilisation du durvalumab en consolidation après radio-chimiothérapie dans les CBNPC de stade III non résécables : cohorte française de PACIFIC-R

Autor: C. Chouaid, E. Pichon, M. Wislez, P. Giraud, W. Hilgers, C. Daniel, M. Pérol, K. Chouahnia, S. Ano, M. Giaj Levra, C. Correia Da Silva, L. Falchero

Publikováno v: Revue des Maladies Respiratoires Actualités. 14:60-61

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d57f4abfffaa3434538a7ecc3abb175
https://doi.org/10.1016/j.rmra.2021.11.550